In April, the [US Centers for Disease Control and Prevention (CDC)](https://www.cdc.gov/mmwr/volumes/69/wr/mm6914a2.htm){#interrefs10} updated their recommendations for hepatitis C virus (HCV) screening in the USA. The revised guidelines reflect increasing evidence suggesting that not only is HCV more prevalent than before, but also that awareness of infection status is low: in a [National Health and Nutrition Examination Survey (NHANES)](https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13060){#interrefs20} using data from 2013--16, 56% of participants who participated in serology testing for viral hepatitis were unaware they had an HCV infection. These new recommendations are consistent with those from the [US Preventive Services Task Force (USPSTF)](https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-recommendation-statement/hepatitis-c-screening){#interrefs30}, which also propose screening in adults aged 18 years or older; while the USPSTF guidance sets an upper limit of age 79 years, the CDC does not. The CDC guidance also goes one step further by recommending that all pregnant women should be screened for HCV during each pregnancy.

This change in guidance is based on data that show that previous risk-based strategies no longer include people most at risk of HCV infection. Historically, one-time HCV screening was recommended by the CDC for all people born between 1945 and 1965, since this generation had the highest prevalence of infection. But times have changed, and with them, so have demographics. According to the CDC report, just as many people born between 1981 and 1996 (ie, 24--39-year-olds) had chronic HCV as those born between 1945 and 1965. The annual rate of acute HCV cases increased most in young people: in 2018, 3·1 cases of HCV per 100 000 occurred in people aged 20--29 years, compared with 0·9 per 100 000 in people aged 50--59 years and 0·4 per 100 000 in those aged 60 years or older. Injection drug use---particularly opioids---is thought to be largely responsible for the increased prevalence in young people. The growing number of pregnant women who have opioid use disorder and the concurrent increase in HCV infection in women giving birth has prompted the recommendation that screening should be extended to pregnant women. [Between 2006 and 2014](https://www.cdc.gov/mmwr/volumes/68/wr/mm6839a1.htm){#interrefs40}, the incidence of HCV infection in pregnant women nearly doubled and around 1700 infants were born with HCV infection each year between 2011 and 2014.

Although it is crucial that screening recommendations adapt to the circumstances and recognise emerging trends of infection, there are still challenges that need to be overcome if global WHO HCV elimination targets are to be met by 2030. While screening and diagnosis are important, several hurdles remain once a diagnosis has been made. A cure for HCV is available; however, the success of direct-acting antiviral therapy depends not only on identifying people most in need of treatment, but also on treatment access, uptake, and adherence after diagnosis. Barriers to care, including perceived stigma, financial concerns, and logistical difficulties in attending clinics during follow-up, also need to be overcome and efforts to address these issues should go hand-in-hand with screening efforts. As demonstrated in a recent [modelling study](https://doi.org/10.1016/S0140-6736(18)32277-3){#interrefs50}, global WHO HCV elimination targets could be met by 2032, but only if coverage of prevention, screening, and treatment are improved. These projections were made before the COVID-19 pandemic; it seems likely that the pandemic will have a negative impact on efforts to meet the elimination targets.

There is a precedent for successful mass-screening campaigns for HCV. In 2018, the [Egyptian Ministry of Health](https://www.nejm.org/doi/full/10.1056/NEJMsr1912628){#interrefs60} aimed to screen all adults in the country within 1 year: of the 62·5 million people who were eligible, 50 million were screened and 92% of the 1·1 million identified as HCV-positive were treated for HCV infection, suggesting that screening and treatment can be achieved at scale. Of the participants with information available about virological outcome, 99% had a sustained virological response. The cost of curing each patient in the campaign was US\$131.

Ultimately, many deaths from HCV are preventable and identifying people at risk should simultaneously reduce morbidity, mortality, and the likelihood of transmission. Increasing the population who are eligible for HCV screening is a step in the right direction, but concerted efforts must be made to guarantee that once cases are identified, they are treated appropriately. Close monitoring of targets is also crucial to ensuring they are met, and should not be forgotten in the wake of the COVID-19 pandemic. Commitments to the elimination of HCV need to persist long after initial targets are met, and only with far-reaching and wide-scale testing will the size of the initial hurdle become apparent.
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